8-K: HCW Biologics Faces Lawsuit Over Unpaid Construction Invoices, Loan Default Risk Looms

HCW Biologics is facing a lawsuit from BE&K Building Group and potential loan default due to unpaid invoices related to the construction of its new headquarters and GMP manufacturing facilities.

Summary

• HCW Biologics is facing a lawsuit from BE&K Building Group, the prime contractor for its new headquarters and GMP manufacturing facilities.
• The lawsuit alleges breach of contract and the forbearance agreement, seeking damages, interest, and costs.
• Several subcontractors have also filed mechanics liens related to unpaid invoices.
• The company previously terminated a credit agreement with Prime Capital Ventures due to repeated delays in funding.
• HCW Biologics made a $1.0 million payment to BE&K in partial satisfaction of amounts owed under a forbearance agreement.
• The company's loan agreement with Cogent Bank contains a discretionary default provision if construction-related payments are not made, leading to the loan being classified as short-term debt.
• HCW Biologics is seeking alternative financing to satisfy the outstanding balances and complete the construction project.
• Fisk Electric Company has also filed a separate complaint against HCW Biologics and other defendants in the BE&K Litigation.

Sentiment

Score: 2

Explanation: The document paints a negative picture due to the lawsuit, potential loan default, and financing challenges. The company's financial stability and future prospects are uncertain.

Positives

• HCW Biologics made a $1.0 million payment to BE&K under a forbearance agreement, potentially mitigating some of the legal risk.

Negatives

• HCW Biologics is facing a lawsuit from BE&K Building Group for breach of contract.
• Subcontractors have filed mechanics liens due to unpaid invoices.
• The Cogent Bank loan is now classified as short-term debt, indicating increased financial risk.
• The company terminated a credit agreement with Prime Capital Ventures due to funding delays, highlighting difficulties in securing financing.
• Fisk Electric Company has also filed a separate complaint against HCW Biologics and other defendants in the BE&K Litigation.

Risks

• The lawsuit from BE&K Building Group could result in significant financial liabilities for HCW Biologics.
• The mechanics liens filed by subcontractors could further complicate the company's financial situation.
• The discretionary default provision in the Cogent Bank loan agreement poses a risk of accelerated repayment.
• The company's ability to secure alternative financing to complete the construction project is uncertain.
• The separate complaint filed by Fisk Electric Company adds another layer of legal complexity and potential financial exposure.

Future Outlook

HCW Biologics is currently seeking an alternative source of financing to satisfy the balances claimed under the mechanics liens and to complete the construction and renovation of the Property.

Management Comments

• The Company intends to respond in a timely fashion to the BE&K Complaint and cross-claims.

Industry Context

The construction industry is currently experiencing supply chain disruptions and rising costs, which may be contributing to the financial difficulties faced by HCW Biologics in completing its construction project. Other biotech companies expanding manufacturing capabilities may be facing similar challenges.

Comparison to Industry Standards

• It is not uncommon for companies undertaking large construction projects to experience cost overruns and delays.
• However, the legal action and potential loan default faced by HCW Biologics are more severe than typical project challenges.
• Comparable companies in the biotech sector, such as Amgen and Genentech, typically have robust project management and financial resources to mitigate such risks.
• The termination of the credit agreement with Prime Capital Ventures suggests a lack of due diligence or unfavorable financing terms compared to industry standards.

Legal Proceedings

• BE&K Building Group, LLC v. HCW Biologics, et al., CACE-25-004668 (Fla. 17 th Cir. Ct. 2025)
• Fisk Electric Company v. HCW Biologics, Inc, et al., CACE-25-005747 (Fla. 17 th Cir. Ct. 2025)

Stakeholder Impact

• Shareholders face the risk of decreased stock value due to the company's financial and legal challenges.
• Employees may experience uncertainty regarding job security due to the company's financial difficulties.
• Suppliers and subcontractors face the risk of non-payment for their services.
• Creditors, including Cogent Bank, face the risk of potential loan default.

Next Steps

• HCW Biologics must respond to the BE&K Complaint by May 7, 2025.
• The company needs to secure alternative financing to satisfy the mechanics liens and complete the construction project.

Key Dates

Keywords

lawsuit, construction, mechanics liens, financing, default, HCW Biologics, BE&K Building Group, Cogent Bank, Prime Capital Ventures, Fisk Electric Company